AIHTA - Publications - Search - Items where Subject is "QT 36-37 Biomedical engineering, nanotechnology, biocompatible materials"
Number of items at this level: 15.

Breyer, E. (2007): [Nanotechnologies in medicine: Hopes and risks]. HTA-Newsletter 60: pp. 2-3.

Eder, C. and Wild, C. (2019): Advanced Therapy Medicinal Products (ATMPs): Technology forecast. Journal of Market Access & Health Policy 7 (1).

Falkner, E. (2007): [Tissue engineering]. HTA-Newsletter 57: p. 3.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Falkner, E. and Eder, C. (2007): Health technology assessment: Evaluation of costs and benefits of therapies & methods. Int. J. Artif. Org. 2007. (In Press)

Falkner, E. and Eder, C. and Wild, C. (2007): Evaluation of regenerative medicine/tissue engineering approaches by health technolgy assessment. Regenerative Medicine 2007. (In Press)

Geiger-Gritsch, S. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: CAR-T Cell Therapy. AIHTA Policy Brief 006a.

Goetz, G. and De Villiers, C. (2019): Allograft for anterior and posterior cruciate ligament reconstruction. Decision Support Document 116.

Künzl, M. and Wild, C. and Mathis, S. and Johansson, T. (2009): Autologous Chondrocyte Implantation. Systematic Review. Decision Support Document 34.

Wild, C. and Wohlhöfner, K. and Sehic, O. and Grössmann, N. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: ATMPs and Gene Therapies. AIHTA Policy Brief 006b.

Wild, C. (2005): [Nanotechnology in medical research]. HTA-Newsletter 38: pp. 3-4.

Wild, C. (2003): [Graftskin (Apligraf®) in the treatment of venous leg ulcers]. HTA-Newsletter 21: pp. 3-4.

Wild, C. (1998): [Delphi-Austria: foresight on medical technologies and social-organisational developments in health care]. Delphi Report Austria 2.

Wild, C. (2015): Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenoses. Decision Support Document 89.

Wild, C. (2012): Cell therapy for urinary stress incontinence. Decision Support Document 06 / Update 2012.

This list was generated on Mon Oct 26 01:00:21 2020 CET.